Mesoblast reaches 300-patient Phase 3 treatment target
Mesoblast (NASDAQ:MESO) treated at least 300 patients in MSB-DR004, reaching the pivotal Phase 3 treatment target for rexlemestrocel-L in chronic low back pain.

Founder and CEO of Grafa, leading the company's vision to democratise financial data and empower investors with innovative tools.
Mesoblast (NASDAQ:MESO) treated at least 300 patients in MSB-DR004, reaching the pivotal Phase 3 treatment target for rexlemestrocel-L in chronic low back pain.
Chinese prosecutors proposed stronger tools to investigate cryptocurrency-related crime, with a focus on privacy coins.
Light & Wonder (ASX:LNW) has reaffirmed its full-year 2026 guidance, projecting mid- to high-single-digit growth in adjusted earnings.
Bitcoin (CRYPTO:BTC) fell as traders increased bets that the US Federal Reserve could raise interest rates after this week's inflation report.
Cazaly Resources (ASX:CAZ) commenced a 3,000-metre aircore drilling programme at its Hastings gold prospect in Western Australia.
Recce Pharmaceuticals (ASX:RCE) expanded its global intellectual property portfolio by securing its eighth Family 4 patent in Vietnam.
Metaplanet completed its purchase of Siiibo Securities and launched Metaplanet Securities.
Gondor launched V1, a lending platform that lets Polymarket traders borrow against their entire portfolio instead of individual positions.
Bitcoin (CRYPTO:BTC) worth about US$188 million moved from a wallet that had been inactive for seven years.
Macro Metals (ASX:M4M) has agreed to buy the Yandi South Project for $6.5 million to boost its iron ore assets.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy